<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403117</url>
  </required_header>
  <id_info>
    <org_study_id>5360</org_study_id>
    <nct_id>NCT00403117</nct_id>
  </id_info>
  <brief_title>Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the subjective effects of marijuana will be
      decreased by low-doses (&lt; 25 mg) of naltrexone and increased by high-doses (&gt; 50 mg) of
      naltrexone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laboratory animal studies demonstrate that endogenous cannabinoids and opioids are closely
      inter-related. We have completed a series of studies in marijuana smokers showing that a
      clinically-utilized dose of naltrexone (50 mg) enhanced the reinforcing and subjective
      effects of orally-administered tetrahydrocannabinol (THC), while a low naltrexone dose (12
      mg) blunted the effects of THC. A better understanding of the effects of a range of
      naltrexone doses in combination with smoked marijuana has important implications for the
      following reasons: (1) Alcohol- and opioid-dependent patients receive high doses of
      naltrexone (50-150 mg), which may increase the abuse liability of marijuana, (2) Low-dose
      naltrexone blunts THC's intoxicating effects, suggesting potential utility as a treatment
      medication for marijuana dependence. This study will determine if naltrexone (0, 12, 25, 50,
      100 mg) administration 45 min prior to marijuana administration (0, 3.9% THC) alters
      marijuana's subjective, cognitive or physiological effects. Marijuana smokers will spend
      approximately 5h/day for a total of 10 days in the outpatient laboratory. Participants will
      visit the outpatient laboratory 2-3 times per week, with a minimum 48-hr interval between
      sessions to allow for naltrexone clearance. These data will provide important information
      regarding the clinical use of naltrexone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>marijuana's subjective effects</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>marijuana's cardiovascular effects</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>marijuana's cognitive effects</measure>
    <time_frame>8 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Marijuana Smoking</condition>
  <arm_group>
    <arm_group_label>naltrexone, marijuana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone (0, 12, 25, 50, or 100 mg) marijuana (3.27 or 0% THC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, marijuana</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>marijuana (3.27 or 0% THC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <arm_group_label>naltrexone, marijuana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <arm_group_label>naltrexone, marijuana</arm_group_label>
    <arm_group_label>placebo, marijuana</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current marijuana use

          -  Able to perform study procedures

          -  21-45 years of age

          -  Women practicing an effective form of birth control

        Exclusion Criteria:

          -  Current, repeated illicit drug use (other than marijuana)

          -  Presence of significant medical illness (e.g., diabetes, cardiovascular disease,
             hypertension, examination, laboratory hepatitis, clinically significant laboratory
             abnormalities, tests, 12-lead ECG, Mantoux test LFTs &gt; 3x upper limit of normal)

          -  History of heart disease

          -  Request for drug treatment

          -  Current parole or probation

          -  Pregnancy or current lactation

          -  Recent history of significant violent behavior

          -  Previous adverse reaction to naltrexone

          -  Major current Axis I psychopathology Psychiatric interview (e.g., major depressive
             disorder, bipolar disorder, suicide risk, schizophrenia)

          -  Current use of any prescription or over-the-counter medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>November 21, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>naltrexone</keyword>
  <keyword>smoked marijuana</keyword>
  <keyword>marijuana use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
